Finally, only one study in stage II CRC patients reported that CD166 expression may become a predictive biomarker of OS and disease-specific survival using multivariate logistic regression analysis [23], which suggests that additional studies with large populations are needed to confirm the predictive role of CD166 expression in CRC patients with the detailed tumor staging. Here, ALCAM is linked to colorectal carcinoma.